Key information

🔎 Fund Overview

Inhibrx, Inc. is a clinical-stage biopharmaceutical company, which is focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company’s pipeline is focused on oncology and orphan diseases. Its clinical pipeline includes therapeutic candidates, such as INBRX-101, and INBRX-109. INBRX-101 is an engineered recombinant human alpha-1 antitrypsin fragment crystallizable (AAT-Fc) fusion protein therapeutic candidate that the Company is developing for the treatment of patients with Alpha-1 Antitrypsin Deficiency (AATD) and acute Graft-versus -host-disease (aGvHD). AATD is an inherited disease that causes an increased risk of developing pulmonary disease defined by progressive loss of lung tissue and function and is associated with decreased life expectancy. INBRX-109 is an engineered tetravalent therapeutic candidate targeting death-receptor 5 (DR5), a TNFRSF member, also known as tumor necrosis factor-related apoptosis-inducing ligand or TRAIL receptor 2.